TMF, good post. I read those same comments on those other boards too. I find it really annoying that so many come to such ridiculous conclusions based on current revenue. As far as I am concerned the revenue we have now is chump change; fortunate to have any revenue given where the company is at with patents, clinical trials, peer reviews, etc... If you think about it this company is really in its infancy since it was only recently discovered that, via CigRX, anatabine seems to help many ailments by way of reducing inflammation. Now that this is known it needs to be proven....which takes time.
What keeps my interest in Star is knowing that it's not impossible for a company in its infancy with a proven product, enormous market potential, minimal revenue, and even a net loss to have a $200 share price.
Tesla Motors is just such a company. It has about a $2 per share net loss but yet the share price is approaching $200.
If Anatabloc proves to be all that many of us believe it to be it will be fun to watch the share price work it's way to three digits.
News 
Market Data 
Discover 
